WELLESLEY HILLS, Mass. — Joseph F. Finn, Jr., C.P.A. (“Finn”) announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia (“CLL”), multiple myeloma (“MM”) and diffuse large B cell lymphoma (“DLBCL”).
In clinical studies, GCS-100 has demonstrated activity as a single agent in CLL and in combination with existing therapy in MM.
The intellectual property, regulatory dossier, fixed assets and clinical inventory of Prospect will be sold at auction on Monday, June 29, 2009 at 12:00 p.m.
Persons interested in bidding must sign a Confidentiality Agreement (“CA”) obtained from Finn’s Office – [email protected] or 781-237-8840. They will then receive a bid package.
About Prospect Therapeutics, Inc.
Prospect’s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or [email protected] or visit the website at www.finnwarnkegayton.com.